表紙
市場調查報告書

流感診斷的全球市場 - 各類型,級端用戶,各地區 - 成長,趨勢,及預測(2018年∼2023年)

Influenza Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 661042
出版日期 內容資訊 英文 118 Pages
商品交期: 2-3個工作天內
價格
Back to Top
流感診斷的全球市場 - 各類型,級端用戶,各地區 - 成長,趨勢,及預測(2018年∼2023年) Influenza Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 118 Pages
簡介

流感診斷市場在2018年到2023年間,預測將以約8.0%的年複合成長率增長。由於發展了為早期診斷和高度的醫療基本設備的認識的高漲,高度的診斷技術的適用,北美市場佔有率壓倒性。

本報告提供流感診斷的全球市場調查,提供市場概要,各類型·級端用戶·地區的市場趨勢,市場規模的變化與預測,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 市場動態

  • 成長要素
  • 阻礙因素
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 試驗類別
    • 傳統的診斷試驗
    • 分子診斷化驗
  • 終端用戶
    • 醫院
    • 研究所
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,聯盟,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • 3M
  • Abbott
  • Becton, Dickinson and Company
  • DiaSorin spa
  • F. Hoffmann-La Roche AG
  • Luminex Corporation
  • Meridian Bioscience, Inc
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc
  • List Not Exhaustive

第10章 未來市場預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 60465

Market Overview

The global influenza diagnostics market was valued at USD 492.42 million in 2018, and is estimated to be valued at USD 731.97 million in 2024, witnessing a CAGR of 6.83%. Certain factors that are driving the market growth include increasing prevalence of influenza and related chronic diseases, growth in research funding for influenza diagnostics, and rising demand for early diagnosis and control of influenza.

Influenza is recognized as a crucial cause of morbidity and mortality in the human population, which is leading to the development and use of diagnostics that are intended for reducing consequent health and economic impacts. According to WHO, in 2018, influenza caused severe sickness or death mainly in patients at a high risk and illness range from mild to severe and even death. Also, this annual increase is projected to result in about 3-5 million cases of severe illness, and about 290,000-650,000 deaths, globally.

Various initiatives and research funding are bolstering the growth of the market. For instance, National Institute of Allergy and Infectious Disease (NIAID) has supported a broad portfolio of the influenza research, which includes studies that are informing the development of vaccines, diagnostics, and therapeutics against seasonal and pandemic influenza. Similarly, in 2018, a non-profit association between academic, government, and industry medical researchers, called Human Vaccine Project, launched the Universal Influenza Vaccine Initiative. Thus, growth in research funding by the government and companies for influenza diagnostics is driving the market.

However, it is critical to ensure that all the rapid antigen flu tests meet new FDA requirements for approval. Hence, the stringent FDA regulations act as significant restraints for the market.

Scope of the Report

Influenza, also known as flu, is a highly contagious infectious disease caused by a virus. This is an infection of the respiratory passages, which causes fever and severe aches. The influenza diagnostic market includes the tests that are conducted for the diagnosis of influenza cases. As per the scope of this report, only the test kits and reagents that are being used for the diagnosis of influenza have been taken into account for the calculation of the total market size.

Key Market Trends

Rapid Influenza Diagnostic Test (RIDT) is Expected to hold its Highest Market Share in the Test Type Segment

In the test type segment of the influenza diagnostics market, among all traditional diagnostic tests, the rapid influenza diagnostic test (RIDT) is believed to have the largest market size and is expected to witness a CAGR of 6.87% during the forecast period.

Rapid influenza diagnostic tests (RIDTs) are immunoassays, which help to identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and qualitatively provide the results. It can diagnose patients, who are present with influenza-like illness, mainly if it is performed within the first four days of the onset of symptoms.

The rising popularity of RIDT is due to the benefits of a faster result and simple usage. Some of the RIDTs are also approved for office/bedside use as well. The RIDT segment is also expected to witness rapid growth, as a result of their common usage in point-of-care settings.

However, one of the major drawback associated with RIDT is that it gives false negative results, due to its low to moderate sensitivities (50-70%). Healthcare policymakers began to recognize the impact of its low sensitivity in 2009 when the novel H1N1 influenza epidemic occurred.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for influenza diagnostics and is expected to continue its stronghold for a few more years.

As per data published by the Centers for Disease Control and Prevention (CDC), RIDTs are commonly available across the region. The reason behind the wide availability of the test is the reduced time span needed to generate results. RIDT can yield results in 15 minutes. With increasing influenza-associated hospitalization and pediatric deaths and the interest of government organizations to better manage the disease, the North American influenza diagnostics market is expected to grow in the future.

Competitive Landscape

The influenza diagnostics market is highly competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Companies, like Coris BioConcept, DiaSorin SpA, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Quidel Corporation, and Sekisui Diagnostics., among others, hold the substantial share in the market.

Various developments have recently been taking place in the market; for instance, in March 2018, Sekisui Diagnostics launched the Silaris Influenza A and B test, developed in collaboration with Mesa Biotech. Also, in October 2017, Abbott Laboratories acquired Alere Inc. (Alere), a diagnostic device and service provider, which strengthened the company's diagnostics presence.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Influenza and Related Chronic Diseases
    • 4.2.2 Growth in Research Funding for Influenza Diagnostics
    • 4.2.3 Rising Demand for Early Diagnosis and Control of Influenza
  • 4.3 Market Restraints
    • 4.3.1 Product Safety and High Cost of Development
    • 4.3.2 Stringent Government Regulations
    • 4.3.3 Variability in Sensitivity and Specificity among Influenza Diagnostic Tests
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Test Type
    • 5.1.1 Traditional Diagnostic Test
      • 5.1.1.1 Rapid Influenza Diagnostic Test (RIDT)
      • 5.1.1.2 Viral Culture
      • 5.1.1.3 Direct Fluorescent Antibody (DFA) Test
      • 5.1.1.4 Serological Assay
    • 5.1.2 Molecular Diagnostic Assay
      • 5.1.2.1 RT-PCR
      • 5.1.2.2 Nucleic Acid Sequence-based Amplification (NASBA) Test
      • 5.1.2.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)
      • 5.1.2.4 Simple Amplification-based Assay (SAMBA)
      • 5.1.2.5 Other Molecular Diagnostic Assays
  • 5.2 End User
    • 5.2.1 Hospital
    • 5.2.2 Research Laboratory
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Coris BioConcept
    • 6.1.4 DiaSorin SpA
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Luminex Corporation
    • 6.1.7 Meridian Bioscience Inc.
    • 6.1.8 Quidel Corporation
    • 6.1.9 Sekisui Diagnostics
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top